Benign Proliferative Breast Lesions and Risk of Cancer

Yıl 2010, Cilt: 19 Sayı: 3, 155 - 167, 01.09.2010

Serap Erel

Öz

Benign breast lesions (BBL) includes a wide variety of histologic entities, which have been broadly classified into non-proliferative lesions, proliferative lesions without atypia, and hyperplasia with atypia. With the increased use of mammography, more benign lesions are being detected, and in order to estimate the risk of breast cancer for specific histologic categories is of great importance to guide clinical management. Women with proliferative lesions without atypia are at slightly increased risk of subsequent breast cancer, whereas women with proliferative lesions with atypia have a higher risk. The risk is 1.5- 2-fold in women with proliferative lesions without atypia, 4-5-fold in women with proliferative lesions with atypia, and 8-10 fold in women with ductal carcinoma in situ. Age at diagnosis of BBL, menopausal status, family history of breast cancer in a first-degree relative, and time since BBL diagnosis on risk of breast cancer are important for risk evaluation.

Anahtar Kelimeler

Proliferative lesions, mammografi, cancer risk, atypia.

Memenin Benign Proliferatif Lezyonları ve Kanser Riski

Öz

Benign meme lezyonlarının non-proliferatif lezyonlardan atipili ve atipisiz proliferatif lezyonlara kadar sınıflandırılan geniş histolojik kapsamı vardır. Mamografinin yaygınlaşan kullanımıyla daha çok benign lezyon tespit edilmektedir ve klinik yaklaşıma rehber olması amacıyla özellikli histolojik gruplar için meme kanseri riskinin tam olarak belirlenmesi önem kazanmaktadır. Atipisiz proliferatif meme lezyonları olan kadınlarda invazif kanser gelişmesi riski az miktarda artmıştır, buna rağmen atipili proliferatif lezyonlu kadınlarda risk daha yüksektir. Atipisiz proliferatif lezyonlarda risk 1,5-2 kat, atipili proliferatif lezyonlarda risk 4-5 kat ve duktal karsinoma in situ da 8-10 kat risk mevcuttur. Ayrıca biyopsi anındaki yaş, menopoz durumu, birinci dereceden yakınında meme kanseri hikayesi ve benign meme lezyonu tanısından sonra geçen süre de risk hesaplamalarında önemlidir.

Anahtar Kelimeler

Proliferatif lezyonlar, mamografi, kanser riski, atipi

Kaynakça

• Foster MC, Helvie MA, Gregory NE, et al. Lobular carcinoma in situ or atypical lobular hyperplasia at core-needle biopsy: is excisional biopsy necessary? Radiology 2004; 231:813 -9
• Brem RF, Behrndt VS, Sanow L, et al. Atypical ductal hyperplasia: histologic underestimation of carcinoma in tissue harvested from impalpable breast lesions using 11-gauge stereotactically guided directional vacuum-assisted biopsy. AJR 1999;172: 1405-7.
• Jacobs TW, Connolly JL, Schnitt SJ. Nonmalignant lesions in breast core needle biopsies: to excise or not to excise? Am J Surg Pathol 2002; 26: 1095-110
• Sklair-Levy M, Sella T, Alweiss T, et al. Incidence and management of complex fibroadenomas. AJR Am J Roentgenol. 2008 190(1): 214-8.
• Tran PV, Lui PC, Yu AM, et al. Atypia in fine needle aspirates of breast lesions. J Clin Pathol 2010;63:585-91
• Masood S, Frykberg ER, McLellan GL, et al. Cytologic differentiation between proliferative and nonproliferative breast disease in mammographically guided fine needle aspirates. Diagn Cytopathol. 1991; 7: 581-90.
• Zhao C, Raza A, Martin SE, et al. Breast fine-needle aspiration samples reported as "proliferative breast lesion": clinical utility of the subcategory "proliferative breast lesion with atypia". Cancer Cytopathol. 2009 117(2):137-47.
• Tavassoli FA, Hoefler H,Rosai J, et al. Intraductal Proliferative Lesions. In: Tavassoli FA, DevileeP, eds. World Health Organization Classification of Tumors. Pathology & Genetics: Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003: 63–73.
• Robbins Basic Pathology, 8th Edition, by V. Kumar, R. Cotran and S. Robbins, Saunders, 2007.
• Schnitt SJ. Benign breast disease and breast cancer risk: morphology and beyond. Am J Surg Pathol 2003;27: 836-41.
• Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl JMed 2005;353: 229-37.
• Marshall LM, Hunter DJ, Connolly JL, et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev 1997; 6: 297- 301.
• JacobsTW, Byrne C, Colditz G, et al. Radial scars in benign breast-biopsy specimens and the risk of breast cancer. N Engl J Med 1999; 340:430-36.
• Goehring C, Morabia A. Epidemiology of benign breast disease, with special attention to histologic types. Epidemiol Rev 1997;19: 310-27
• López-Medina A, Cintora E, Mşgica B, et al. Radial scars diagnosed at stereotactic core- needle biopsy: surgical biopsy findings. Eur Radiol 2006; 16: 1803–10
• Cawson JN, Malara F, Kavanagh A, et al. Fourteen-gauge needle core biopsy of mammographically evident radial scars: is excision necessary? Cancer 2003; 97: 345–51
• Brenner RJ, Jackman RJ, Parker SH, et al. Percutaneous core needle biopsy of radial scars of the breast: when is excision necessary? AJR 2002; 179:1179–84
• Resetkova E, Edelweiss M, Albarracin CT, et al. Management of radial sclerosing lesions of the breast diagnosed using percutaneous vacuum-assisted core needle biopsy: recommendations for excision based on seven years' of experience at a single institution. Breast Cancer Res Treat 2008; Jul 15 (Epub ahead of print)
• Gendler LS, Feldman SM, Balassanian R, et al. Association of breast cancer with papillary lesions identified at percutaneous image-guided breast biopsy. Am J Surg 2004;188: 365-70.
• Skandarajah AR, Field L, Yuen Larn Mou A, et al. Benign papilloma on core biopsy requires surgical excision. Ann Surg Oncol 2008;15: 2272-7
• Page DL, Salhany KE, Jensen RA, et al. Subsequent breast carcinoma risk after biopsy with atypia in a breast papilloma. Cancer 1996;78: 258-66.
• Arpino G, Laucirica R, Elledge RM. Premalignant and in situ breast disease: biology and clinical implications. Ann InternMed 2005;143: 446-57.
• Pinder SE, Ellis IO. The diagnosis and management of pre-invasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH)--current definitions and classification. Breast Cancer Res 2003;5: 254–7
• Webb PM, Byrne C, Schnitt SJ et al. Family history of breast cancer, age, and benign breast disease. Int J Cancer 2002;100: 375–8.
• Page DL, Dupont WD, Rogers LW et al. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 1985;55: 2698–708.
• Tavassoli FA, Norris HJ. A comparison of the results of long-term follow-up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast. Cancer 1990;65: 518–29.
• Collins LC, Baer HJ, Tamimi RM, et al. Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses' Health Study. Cancer. 2007;109:180-7.
• Renshaw AA, Cartagena N, Schenkman RH, et al. Atypical ductal hyperplasia in breast core needle biopsies. Correlation of size of the lesion, complete removal of the lesion, and the incidence of carcinoma in follow-up biopsies. Am J Clin Pathol. 2001 Jul;116(1): 92-6.
• Haagensen CD, Lane N, Lattes R, et al. Lobular neoplasia (so called lobular carcinoma in situ) of the breast. Cancer 1978;42: 737-69.
• O'Neil M, Madan R, Tawfik OW, et al. Lobular carcinoma in situ/atypical lobular hyperplasia on breast needle biopsies: does it warrant surgical excisional biopsy? A study of 27 cases. Ann Diagn Pathol. 2010 Aug;14(4):251-5.
• Page DL, Kidd TE, Dupont WD, et al. Lobular neoplasia of the breast: higher risk for
• subsequent invasive cancer predicted by more extensive disease. Hum Pathol. 1991;22: 1232-9.
• Franceschi S, Levi F, La Vecchia C, et al. Second cancers following in situ carcinoma of the breast. Int J Cancer. 1998;77: 392-5.
• Frykberg ER, Santiago F, Betsill WL, et al. Lobular carcinoma in situ of the breast. Surg Gynecol Obstet. 1987;164:285-301
• Newman L. Lobular carcinoma in situ: clinical management. In: Harris JR, Lippman ME, Morrow M, et al, eds. Diseases of the Breast. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 2004.
• Bradley SJ, Weaver DW, Bouwman DL. Alternatives in the surgical management of in situ breast cancer. A meta-analysis of outcome. Am Surg. 1990;56: 428-32.
• Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breastand Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90: 1371-88.
• Barnes R, Masood S. Potential value of hormone receptor assay incarcinoma in situ of breast. Am J Clin Pathol. 1990;94: 533-7.
• Zhao C, Raza A, Martin SE, et al. Breast fine-needle aspiration samples reported as ‘‘proliferative breast lesion’’: clinical utility of the subcategory ‘‘proliferative breast lesion with atypia’’ Cancer (Cancer Cytopathol) 2009;117:137–47.
• Graf O, Helbich TH, Fuchsjaeger MH, et al. Followup of palpable circumscribed noncalcified solid breast masses at mammography and US: can biopsy be averted? Radiology 2004; 233:850–6
• Sickles EA. Probably benign breast lesions: when should follow-up be recommended and what is the optimal follow-up protocol? Radiology 1999;213: 11–14.
• Perry N, Broeders M, de Wolf C, et al. European Guidelines for Quality Assurance in Breast
• Cancer Screening and Diagnosis. 4th ed. Luxembourg: Office for Official Publications of the EuropeanCommunities; 2006.